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Abstract
Objective—Genomic studies of ovarian cancer (OC) cell lines frequently used in research 
revealed that these cells do not fully represent high-grade serous ovarian cancer (HGSOC), the 
most common OC histologic type. However, OC lines that appear to genomically resemble 
HGSOC have not been extensively used and their growth characteristics in murine xenografts are 
essentially unknown.
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Methods—To better understand growth patterns and characteristics of HGSOC cell lines in vivo, 
CAOV3, COV362, KURAMOCHI, NIH-OVCAR3, OVCAR4, OVCAR5, OVCAR8, OVSAHO, 
OVKATE, SNU119, UWB1.289 cells were assessed for tumor formation in nude mice. Cells were 
injected intraperitoneally (i.p.) or subcutaneously (s.c.) in female athymic nude mice and allowed 
to grow (maximum of 90 days) and tumor formation was analyzed. All tumors were sectioned and 
assessed using H&E staining and immunohistochemistry for p53, PAX8 and WT1 expression.
Results—Six lines (OVCAR3, OVCAR4, OVCAR5, OVCAR8, CAOV3, and OVSAHO) 
formed i.p xenografts with HGSOC histology. OVKATE and COV362 formed s.c. tumors only. 
Rapid tumor formation was observed for OVCAR3, OVCAR5 and OVCAR8, but only OVCAR8 
reliably formed ascites. Tumors derived from OVCAR3, OVCAR4, and OVKATE displayed 
papillary features. Of the 11 lines examined, three (Kuramochi, SNU119 and UWB1.289) were 
non-tumorigenic.
Conclusions—Our findings help further define which HGSOC cell models reliably generate 
tumors and/or ascites, critical information for preclinical drug development, validating in vitro 
findings, imaging and prevention studies by the OC research community.
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Introduction
Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths among women in the 
US and the most lethal gynecologic malignancy[1]. The five-year survival rate has remained 
close to 25%, and all women are currently treated with the same approach consisting of 
surgical debulking followed by chemotherapy composed of paclitaxel and carboplatin[2]. 
Diagnosis of OC usually occurs after metastasis at stage II–IV, and this contributes to the 
poor survival [3]. Targeted therapies and better strategies for early detection would increase 
survival, but adequate model systems to study the disease remain a major challenge facing 
the gynecologic oncology research field [4, 5].
Ovarian cancer is a heterogeneous disease that includes at least five histotypes: clear cell, 
endometrioid, mucinous, low-grade serous, and high-grade serous tumors [6, 7]. 
Heterogeneity may be a result of the cell of origin that gives rise to different forms of the 
disease and reflects distinct molecular alterations associated with each histotype[8–10]. 
High-grade serous ovarian cancer (HGSOC), the most common and deadly form of the 
disease, is considered the “prototype” of epithelial OC, and the recent Cancer Genome Atlas 
Network analysis defined the landscape of deregulated pathways characterizing 
HGSOC[11]. Specifically, these tumors are classified based upon mutation of p53, 
BRCA1/2 mutation, somatic loss, or methylation, and a variety of protein markers including 
PAX8 and WT1. In addition, copy number variation is a hallmark of HGSOC and less 
commonly found in endometrioid, clear cell, and mucinous histotypes [12]. Recent genetic 
signatures from primary human tumors further divided HGSOC into four molecular groups, 
namely immunoreactive, proliferative, differentiated, and mesenchymal [13]. While these 
categories are well established in primary and recurrent HGSOC tumors, the ability to 
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correlate genomic and molecular features with useful laboratory model systems is critical for 
the future development of new therapies, prevention strategies, and imaging studies [14].
Recent publications have characterized an expanded panel of OC cell lines at the genomic 
level, in 2-dimesional-cell culture (on plastic), and in regards to their in vitro response to 
chemotherapeutic drugs [15–17]. These reports further suggested that OC cell lines 
commonly used in the past (e.g. SKOV3, A2780) do not represent a good approximation of 
the HGSOC genotype and that a panel of recently described cell lines more closely resemble 
human serous tumor. However, several of the newly proposed models for HGSOC have 
never been characterized for the ability to form tumors in immune deficient mice, which is 
critical to study mechanisms of disease or therapeutic interventions in vivo. The goal of this 
study was to determine the tumorigenic ability of newly described HGSOC cell lines and the 
histologic characteristics of the xenografts derived from these cells.
Materials and Methods
Cell culture
All reagents were obtained from Life Technologies (Carlsbad, CA) unless otherwise 
indicated. OVCAR4 was obtained through Material Transfer Agreement (MTA) from the 
National Cancer Institute for the transfer of cell lines from the Division of Cancer Treatment 
and Diagnosis Tumor Repository. The DCTD Tumor Repository has maintained, since the 
early 1960's, a low temperature repository of transplantable tumor and tumor cell lines from 
various species. OVCAR4 were maintained in RPMI supplemented with 10% fetal bovine 
serum (FBS), 2mM L-glutamine, and 100U/ml penicillin/streptomycin. Kuramochi, 
OVSAHO, and OVKATE were obtained through MTA from the Japanese Collection of 
Research Bioresources Cell Bank (JCRB). The JCRB cells were cultured in RPMI 1640 
medium with 10% FBS. NIH:OVCAR3, CAOV3 and UWB1.289 cells were purchased from 
ATCC (1/2014). NIH:OVCAR3 cells were maintained In RPMI-1640 Media supplemented 
with 20% FBS, 0.01mg/ml insulin and 50 U/mL penicillin, and 50µg/mL streptomycin. 
CAOV3 cells were grown in Dulbecco’s Modified Eagles Medium containing 10% FBS and 
50 U/mL penicillin, and 50 µg/mL streptomycin. OVCAR5 cells were obtained from the 
Developmental Therapeutics Program at National Cancer Institute and cultured in DMEM, 
10%FBS, 1% PSG, and 0.1mM MEM Non-essential amino acids. OVCAR8 cells were 
obtained from ATCC and cultured in DMEM with 10% FBS. COV362 were from Adam 
Karpf, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska 
Medical Center and grown in DMEM with L-glutamine (300mg/L) and 10% heat 
inactivated fetal bovine serum. SNU-119 were sourced from the Korean Cell Line Bank 
(also obtained from Dr. Karpf) and grown in RPMI1640 with L-glutamine (300mg/L), 
25mM HEPES and 25mM NaHCO3, 90%; heat inactivated fetal bovine serum (FBS), 10%. 
UWB1.289 cells were cultured in media composed of 1:1 RPMI-1640 and Mammary 
Epithelial Growth Medium (MEGM, Lonza #CC-3150) supplemented by 3% FBS. 
Information regarding mycoplasma testing, in vitro doubling times, and STR validation is in 
Supplemental Table 1.
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Study approval
All animals were treated in accordance with the NIH guidelines for Laboratory Animals and 
established Institutional Animal Use and Care protocols at the University of Illinois at 
Chicago, Indiana University School of Medicine, Indiana University, Bloomington, and 
University of Notre Dame.
Xenografting
6–7 weeks old female athymic (nude) mice were acquired from (Harlan Teklad, 
Indianapolis, IN) and xenografted with human OC cells 1×106 cells subcutaneously (s.c) and 
5×106 cells intraperitoneally (i.p.) in sterile PBS. Animal body weight and s.c. tumor growth 
(via caliper measurement) were tracked weekly and animals sacrificed when tumor burden 
was evident or general health was determined to be moribund. If no tumor formation was 
evident, animals were sacrificed after 90 days of tumor implantation.
Tissue collection and analysis
At the time of sacrifice, s.c. and i.p. tumors were dissected and weighed, and evidence of i.p. 
disease was noted by photography and charted based on organ of dissemination. Tissues 
were fixed in 4% paraformaldehyde before dehydration in ethanol and xylene prior to 
paraffin embedding. Immunohistochemistry and hematoxylin and eosin (H&E) staining was 
performed as previously described [18]. Briefly, tissues were sectioned and rehydrated in a 
gradient of ethanol prior to antigen retrieval and peroxidase block. Sections were incubated 
in primary antibody overnight at 4°C before detection via biotinylated secondary antibody 
(1:200, Vector Laboratories (Burlingame, CA) and ABC peroxidase (Vector Laboratories). 
Targets were visualized via 3,3’-diaminobenzidine (DAB, Vector Laboratories) and 
counterstained with hematoxylin. The following antibodies were used in the study: p53 
(Santa Cruz Biotechnology sc-6243 dilution 1:50), Pax8 (Proteintech 10336-1-AP dilution 
1:150), and WT1 (Abcam ab89901 dilution 1:50).
Results
To assess which HGSOC cell lines recapitulate OC clinical features in vivo, xenograft 
assays and pathologic characterization of resulting tumors were performed. Kuramochi, 
OVSAHO, SNU118, COV362, and OVCAR4 were the top five most likely to be high-grade 
serous ovarian cancer according to the genomic data analysis published by Domcke et al.
[17]. The same report identified CAOV3, OVCAR3, and OVCAR8 as possible 
representatives of high-grade serous cancer. Additionally, CAOV3, Kuramochi, OVCAR3, 
OVCAR4, OVCAR5, and OVCAR8 were identified as high grade serous by Anglesio et 
al[15]. UWB1.289 was chosen because it is BRCA-null[19]. Eleven OC cell lines were 
injected i.p. and/or s.c. into female nu/nu mice and tumor formation was assessed after 
observation (up to 90 days). Six of the cell lines (OVCAR3, OVCAR4, OVCAR5, 
OVCAR8, CAOV3, and OVSAHO) formed i.p xenografts (Figure 1, Table 1) and 
considered tumorigenic. OVKATE and COV362 only formed s.c. tumors after 90 days and 
77 days respectively with no evidence of tumor formation in the i.p. grafted mice. No tumor 
formation (either i.p. or s.c) was observed for Kuramochi, UWB1.289, and SNU119 after 90 
days of observation, and these three OC lines were considered to be non-tumorigenic. The 
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data in Table 1 summarizes the average survival, number of tumors per mouse, and p53 
mutational status for the cell lines evaluated[19–21].
As shown in Figure 1, the OVCAR 3 cell line formed the largest (P< 0.05) s.c. tumors by 
mass (400–970 mg by 36 days). OVCAR8 formed the largest i.p. tumors (1004–1509 mg by 
27 days). The most rapid s.c. tumor formation was observed for OVCAR5 (26 days), 
OVCAR8 (27 days) and OVCAR3 (36 days), but s.c. tumor formation for the other cell lines 
tested took longer than 2 months (see Suppl. Fig. S1 for s.c. growth rate for tumors derived 
from OVCAR4, OVKATE and COV362 cells). For i.p. injections, 100% tumor take was 
seen for OVCAR3, OVCAR4, OVCAR5, OVCAR8, and CAOV3 cell lines, but only 80% 
for OVSAHO cells. The macroscopic appearance and distribution of i.p. tumors formed is 
shown in Figure 2.
The location of metastasis in the peritoneal space after i.p. injection was also examined. 
Disseminated tumorigenic cells were observed on peritoneal surfaces, the gastrointestinal 
tract, particularly the small bowel, and the omentum (Table 2), all typical sites of metastasis 
encountered in women with advanced stage HGSOC[5]. OVCAR3 tumors were the most 
widely metastatic, but interestingly malignant ascites formation was not recorded and gross 
metastases to the diaphragm were uncommon, despite the high tumorigenic potential of this 
OC line. For the models that formed i.p. disease, tumors in the GI tract were observed for all 
six cell lines, with the liver and reproductive tissues representing the other most common 
tumor sites. Only OVCAR8 consistently formed ascites fluid when grafted i.p. (within 90 
days).
The microscopic appearance of OVAR3, OVCAR4, OVCAR5, OVCAR8, CAOV3, and 
OVSAHO derived xenografts was consistent with HGSOC histology (Figure 3). OVKATE 
and COV362 were also consistent in HGSOC histology, but as s.c. tumors only (neither line 
formed tumors i.p.). Strong nuclear staining for PAX8 and WT1, characteristic of HGSOC, 
was observed in OVCAR3, OVCAR4, CAOV3, OVCAR8, OVSAHO and OVKATE 
xenografts. Patchy and fainter PAX8 and WT1 nuclear staining was seen in OVCAR5 
tumors (Figure 3 and Table 3). Strong nuclear p53 staining was observed in OVCAR3, 
OVCAR4, and OVKATE tumors, and faint p53 staining characterized OVSAHO, CAOV3, 
and OVCAR8 xenografts. Interestingly, OVCAR5 tumors were p53 negative (Figure 3), and 
tumorigenesis was also the most rapid for this line (Table 1). The published p53 mutation 
present in each cellular model is reported in Table 1. COV362 s.c. tumors only stained 
positively for Pax8 and not for WT1 or p53.
Discussion
Validation and comprehensive characterization of genetically and phenotypically defined 
human cell models are essential for the success of biomedical research to treat and prevent 
ovarian carcinoma. The cellular models most commonly used in the literature, such as 
SKOV3 and A2780, have been questioned as being valid models of the most deadly and 
common OC histotype, high grade serous carcinoma[15, 17]. While a few very recent 
publications have provided invaluable characterization of the mutational and growth 
characteristics of more representative cellular models of HGSOC, most of these have not 
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been studied in terms of their growth as a xenograft[15–17], and equally importantly the 
tumorigenic ability of these lines as xenografts in nude mice is unknown and thus their true 
potential for studying human HGSOC is uncertain.
The current study is the first to compile and directly compare the in vivo xenograft 
characteristics of several HGSOC cellular models. Intriguingly, of the top five models 
suggested for use based on genomic sequencing, including Kuramochi, OVSAHO, SNU119, 
COV362, and OVCAR4, only two formed intraperitoneal tumors in athymic nude mice 
within 90 days. Furthermore, we show that of the cell models that in vivo most resemble the 
papillary characteristic of high-grade serous cancer (OVCAR3, OVCAR4, and OVKATE), 
only OVKATE formed s.c. xenograft tumors within 90 days, although it is possible that 
xenografting a higher number of cells for a longer period might result in i.p. disease. Of the 
11 cell models examined in this study, only OVCAR8 reliably demonstrated ascites 
formation within 90 days, and SNU119, Kuramochi, and UWB1.298 all failed to form 
tumors. Overall, we demonstrate the utility of several cellular models for in vivo 
xenografting and illustrate their unique peritoneal dissemination pattern.
In vivo growth characteristics of HGSOC cell models may help dictate their application. For 
example, OVCAR3, OVCAR5, and OVCAR8, the most aggressive lines based on their 
rapid growth in vivo, may be useful to reduce the length and cost of xenograft studies. 
However, because OVCAR5 and OVCAR8 i.p. tumor growth is widely disseminated, it may 
be a challenge to quantitate initial tumor burden as well as changes in tumor growth in 
response to therapy. Take rates were remarkably consistent between the cell models that 
produced tumors, suggesting that if grafted, these models are reliable. OVSAHO and 
OVKATE were both very slow growing in vivo and in vitro, and it seems reasonable to 
suggest that they would both form i.p. disease with more cells or more time. OVCAR3 and 
OVCAR8 formed the largest tumor masses and these lines may be extremely useful in 
conjunction with in vivo optical imaging technologies or drug accumulation and 
biodistribution studies with nanocarriers. For the cells that formed tumors, there was a 
remarkable divergence in organs colonized, although the organs were similar to those seen 
in human disease. All cell models colonized the GI tract and liver and the second most 
common site of tumor formation was the reproductive tract, suggesting that these models 
may be appropriate to study interactions between tumor cells and the microenvironment, in 
general as well as at specific sites in vivo.
In this initial analysis, there was no apparent correlation between the mutational spectrum of 
the cell lines and in vivo growth characteristics. All of the models in this study have p53 
mutations except for OVCAR5, which is p53 null. Otherwise the mutational spectrum for 
these lines is dramatically different, and each could therefore be a model for a specific 
target, such as BRCA1 (for COV362 as a s.c. model), c-myc (COV362 as a s.c. model), 
cyclin E (OVCAR3), mutation in ERBB2 (OVCAR8) or loss of Rb (OVSAHO)[17]. 
Interestingly, previous reports based on in vitro immunocytochemistry studies performed on 
the cell lines found CAOV3 and OVCAR4 to be negative for p53 and WT1. In contrast, our 
in vivo study found that these markers are expressed in tumors from both of these cell lines 
[16]. OVCAR5 and OVCAR3 were identical at the cellular and tumor level for p53 and 
WT1 expression. OVCAR8 expressed WT1 mostly in the nucleolar compartment, which has 
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previously been described in mucinous tumors [22]. Only three of the models tested here in 
vivo (COV362, OVCAR3, and CAOV3) were also screened for chemotherapy sensitivity in 
vitro[16]. All three models appeared to be relatively sensitive to chemotherapy and also had 
almost exactly the same doubling time in vitro, between 51–56 hours [16], yet in vivo 
OVCAR3 was much more aggressive (Figure 1). In summary, the development of more 
reliable and authenticated models of HGSOC has been dramatically improved by recent 
reports characterizing their genomes, behavior in vitro, and sensitivity to drugs. This report 
adds to the growing information and helps to define which HGSOC models reliably generate 
tumors and/or ascites, essential information for their use in drug discovery, imaging, and 
prevention studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Eleven human cell models of high-grade serous ovarian cancer were tested in 
vivo tumor formation.
• OVCAR3, OVCAR5, and OVCAR8 were the most aggressive and OVCAR8 
formed ascites.
• All six models formed peritoneal disease mimicking human cancer expressing 
p53, Pax8, and WT1.
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Figure 1. 
Average tumor weight. Animals were sacrificed at 90 days unless tumor burden required 
euthanasia at an earlier time point (summarized in Table 1). Most cell models formed both 
intraperitoneal (i.p.; left) and subcutaneous (s.c.; right) tumors, but OVSAHO only formed 
IP and OVKATE and COV362 only formed SC.
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Figure 2. 
Intraperitoneal (i.p.) dissemination of ovarian cancer cell lines in athymic nude mice. Cell 
models demonstrated unique sites of colonization (summarized in Table 2). Pictures are 
shown at time of dissection from a representative mouse with i.p. tumors
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Figure 3. 
Human ovarian cancer cell models form high-grade serous tumors based on histology and 
protein expression. Cell models that formed intraperitoneal tumors are shown except for 
OVKATE and COV362, which only grew subcutaneous tumors. Histology and 
immunohistochemical staining of PAX8, WT1, and p53 are shown for human cell models. 
Scale bars equal 50 microns.
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Table 3
Summary of immunohistochemistry
All results are from i.p. tumors except for OVKATE and COV362, which only formed s.c. tumors.
OVCAR3 OVCAR4 OVCAR5 OVCAR8 CAOV3 COV362 OVSAHO OVKATE
PAX8 + + − + + + + +
WT1 + + − nucleolar + − + +
p53 + + null weak + − + +
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